About: Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article published in Journal of Hepatology

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2018 (fr) im Oktober 2018 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована в жовтні 2018 (uk) scholarly article published in Journal of Hepatology (en)
publication date	wds:Q58020766-0CBED6D9-174A-4238-971E-92181FEDB75C
publication date	2018-10-01 00:00:00Z (xsd:dateTime)
rdfs:label	Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (nl) Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] (en)
skos:prefLabel	Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (nl) Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] (en)
name	Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (nl) Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] (en)
author	wds:Q58020766-201F31FD-9D84-44A1-A201-DC27A720E7AA wds:Q58020766-2232CD7B-43A7-49A8-8620-603037C74FB0 wds:Q58020766-C354C7B0-FAAD-4E98-B310-9B30BEE95CAD wds:Q58020766-D82ABB52-D09A-43B7-A0DC-67DBF6136E0C wds:Q58020766-EBF2A9A2-4C37-4A0E-B3DB-454918B50A2D wds:Q58020766-F8B5A3D9-CD89-404C-AE1C-BCB66274AA56
author	Josep M. Llovet Ann-Lii Cheng Jordi Bruix Gerold Meinhardt Yoriko De Sanctis Keiko Nakajima
title	wds:Q58020766-4D3C8F7D-E921-450C-8016-F86CFC25FEE9
title	Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] (en)
page(s)	wds:Q58020766-22F35F8D-A275-45FE-AC09-8CB916B0FC1E
page(s)	990-991
instance of	wds:Q58020766-06DAF59A-47B5-4FC4-8052-3065CE2A843D wds:Q58020766-AD92A26D-EB56-4605-97B7-15A0B3D40A64
instance of	erratum scholarly article
main subject	wds:Q58020766-DC47EF3E-EAFF-4455-8861-8D68497D7853 wds:Q58020766-F2E5C0AF-5954-45F5-85C1-1C4CC15CB47A
main subject	hepatocellular carcinoma Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
PubMed ID	wds:Q58020766-BA7AF404-1068-4DA6-9851-181606E5F04E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30104026
PubMed ID	30104026
published in	wds:Q58020766-43E0DF10-DC26-439B-B411-A56981D6ACA8
published in	Journal of Hepatology
issue	wds:Q58020766-E1C8F8B4-02E5-4345-8FC7-D225E761F7A1
volume	wds:Q58020766-C756C807-DE27-49EF-98F9-B5B9816E763B
issue	4
volume	69
DOI	wds:Q58020766-74BD0FD5-B83A-433D-9B35-CA47335FB9B9
DOI	http://dx.doi.org/10.1016/J.JHEP.2018.07.015
DOI	10.1016/J.JHEP.2018.07.015
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58020766
is cites work of	Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma
is cites work of	wds:Q90607854-573B42E6-792E-4124-AE66-518A93647FE3
is corrigendum / erratum of	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
is corrigendum / erratum of	wds:Q40131537-01F99A91-46BA-4173-B2A2-A9347B58E4B0

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software